Phase 2a human challenge trial for the experimental influenza medication CC-42344 was extended by Cocrystal Pharma (COCP, Financials). Low infection rates among individuals exposed to the H3N2 virus strain presented difficulties for the research meant to assess the safety, tolerability, and antiviral efficacy of the medicine. This problem has postponed the gathering of significant antiviral data, hence the business asked the UK Medicines and Healthcare Products Regulatory Agency for permission to change a procedure.
The news sharply dropped the stock price of Cocrystal Pharma; shares dropped almost 35% and closed at $2.10. Notwithstanding the setback, the business underlined the promise of CC-42444, which aims at a crucial stage in the influenza A virus replication. Early studies reveal a solid safety profile and the experimental medicine has showed great in vitro efficacy against resistant bacteria.
Using its unique structure-based drug discovery system, Cocrystal Pharma is developing antiviral therapies for influenza, coronaviruses, and other viruses. With up to 650,000 fatalities yearly and billions in financial damages, influenza A still presents a major worldwide health concern, according to the healthcare company. With fast-acting, safe, effective treatments, the business hopes to solve these problems.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。